|
Feb 18
|
|
—
|
AVOID
|
Dr. Scott Gottlieb
Former FDA Commissioner; Board Member (Pfizer, Illumina, UnitedHealth); Partner at NEA (Venture Capital)
|
Gottlieb cites a Wall Street Journal editorial noting FDA leader Vinay Prasad rejected Moderna's (MRNA) mRNA vaccine without a cursory review. This "arbitrary" regulatory behavior increases the cost of capital and unpredictability for the entire sector. Gottlieb notes investment in vaccines and cell/gene therapies is drying up in the US and shifting to China (where half of the global mRNA pipeline now sits). The regulatory environment in the US has become hostile to innovation, making the sector uninvestable in the medium term until leadership changes. A change in FDA administration or successful appeals by pharma companies could reverse sentiment. |
CNBC
Squawk Pod: Baby Formula, A Tax Hike, & The L...
|
|
Feb 14
|
|
—
|
LONG
|
Narrator
Video Narrator
|
The narrator states that quantum supremacy "could mean accelerated progress in areas like drug research, artificial intelligence, defense and finance." These sectors are the direct beneficiaries of quantum utility. The ability to process data in parallel (qubits) rather than sequentially (bits) unlocks capabilities in molecular modeling (Biotech), encryption (Defense), and complex market simulation (Finance) that are currently impossible. Long the downstream sectors that will leverage quantum speed to revolutionize their R&D and operational efficiency. The technology remains experimental; failure to achieve stability means these sectors cannot yet deploy these tools. |
Bloomberg Markets
Can Quantum Computing Power the AI Boom?
|
|
Feb 13
|
|
—
|
LONG
|
Gina Raimondo
Former Commerce Secretary
|
Raimondo defines economic security as "leading in artificial intelligence, leading in biotech and quantum" and states the US must "make sure that we are winning the AI race." The US government views these specific sectors not just as commercial industries but as components of "military might." This implies sustained government funding, defense contracts, and protectionist policies to ensure US hegemony over China in these fields. LONG US strategic technology sectors (AI, Quantum, Biotech) as they are effectively government-backed imperatives. High valuation multiples in tech; potential export controls limiting total addressable market (TAM) in China. |
CNBC
Former Commerce Sec. Gina Raimondo: Economic ...
|
|
Feb 09
|
|
—
|
AVOID
|
Dr. Scott Gottlieb
Former FDA Commissioner; Board Member (Pfizer, Illumina, UnitedHealth); Partner at NEA (Venture Capital)
|
Investment capital is fleeing the vaccine research sector. Gottlieb notes that research into vaccines for Epstein-Barr Virus (EBV), MS, and cancer prevention is being pulled back. The political and regulatory environment has become hostile. It is increasingly difficult to get vaccines through the FDA due to policy changes, and even if approved, the CDC is showing reluctance to recommend them due to anti-vaccine sentiment. Gottlieb states that as a Venture Capital partner, he sees it is "very hard to get a new vaccine program funded" right now. A shift in political sentiment or a new public health crisis forcing a regulatory pivot. |
CNBC
Dr. Scott Gottlieb on Novo Nordisk vs. Hims &...
|